Evaluate Safety and Efficacy of Alveo HP Balloon Dilatation Catheter for Balloon Dilatation of Coronary Artery Stenosis

Prior treatment

• Patients with clinical symptoms consistent with ST-segment elevation myocardial infarction or/and ECG changes within 12 hours prior to the procedure;
• Patients who are participating in the clinical trial of other drugs or medical devices;

Other illness

• Patients who are known to be intolerant to antiplatelet drugs or allergic to contrast media;
• Patients with unprotected left main coronary artery disease;

Other

• Patients with in-stent restenosis;
• Patients who plan to treat 3 or more lesions at the same time;
• Patients with severe calcified lesions;
• Patients in whom the guidewire cannot pass through the lesion;
• Women who are pregnant or lactating;
• Other patients considered by the investigator to be unsuitable for this trial.

• Age ≥ 18 years old, gender is not limited;
• Patients with symptomatic ischemic heart disease who are suitable for percutaneous coronary intervention (PCI);
• Patients with target lesion diameter stenosis ≥ 70% (visually) or chronic total occlusion (CTO) who needed balloon dilatation catheter pre-dilatation;
• Patients or their guardians who can understand the purpose of the trial, voluntarily participate and sign the written informed consent, and can accept follow-up;